Companies Alector
Alector (ALEC): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Alector’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers75th pct.Of 5 peer CEOs
CEO pay, last three years
- $4,255,007FY2023
- $3,666,341FY2024
- $1,995,018FY2025
CEO total pay was $1,995,018 in fiscal 2025, down from $3,666,341 in fiscal 2024.
FY2025: salary $678,100 · bonus $0 · stock awards $422,876 · option awards $558,216
Executives and directors
Arnon Rosenthal · CEONeil Berkley · CFOSara Kenkare-Mitra · PresidentDavid Wehner · Independent DirectorElizabeth Garofalo · Independent DirectorErrol De Souza · Independent DirectorKristine Yaffe · Independent DirectorMark Altmeyer · Independent DirectorPaula Hammond · Independent DirectorRichard H. Scheller · Independent Director
Frequently asked questions
Who was the highest-paid executive at Alector in fiscal 2025?
As disclosed, Arnon Rosenthal (Co-founder, Chief Executive Officer, and Director) was the highest-paid executive at Alector in fiscal 2025, with total compensation of $1,995,018.
How does Alector's chief executive pay compare to its disclosed peer group?
As disclosed, Arnon Rosenthal's total compensation ranked at the 75th percentile of Alector's disclosed peer group.
How did shareholders vote on Alector's executive compensation?
As disclosed, 95.91% of shareholders supported Alector's executive compensation in the latest say-on-pay vote.
How much does Alector spend in total on board compensation for fiscal 2025?
As disclosed, Alector reported total board compensation of $775,898 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Arnon Rosenthal | $678,100 | $0 | $422,876 | $558,216 | $325,488 | $0 | $10,338 | $1,995,018 |
| Co-founder, Chief Executive Officer, and Director | ||||||||
| Sara Kenkare-Mitra | 614,301 | 0 | 77,710 | 17,810 | 314,200 | 0 | 551,129 | 1,575,150 |
| Former President and Head of Research and Development | ||||||||
| Neil Berkley | 455,000 | 91,000 | 128,135 | 219,202 | 152,880 | 0 | 6,242 | 1,052,459 |
| Chief Financial Officer and Chief Business Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Arnon Rosenthal | $1,995,018 | $3,666,341 | $4,255,007 | ↓ −1,671,323 |
| Sara Kenkare-Mitra | 1,575,150 | 2,549,681 | 2,606,214 | ↓ −974,531 |
| Neil Berkley | 1,052,459 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation program is designed to attract, engage, and retain highly qualified executives while incentivizing achievement of our corporate strategic objectives.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer & Partners, LLC |
| Clawback policy | true |
| Anti-hedging | — |
| Anti-pledging | — |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Neil Berkley | OPTION | 2025-11-10 | — | — | 195,000 | — | $191,685 |
| Neil Berkley | RSU | 2025-05-15 | — | — | 38,900 | — | 42,985 |
| Arnon Rosenthal | OPTION | 2025-11-10 | — | — | 522,500 | — | 513,618 |
| Sara Kenkare | RSU | 2025-07-01 | — | — | 54,725 | — | 77,710 |
| Arnon Rosenthal | OPTION | 2025-07-01 | — | — | 45,700 | — | 44,598 |
| Arnon Rosenthal | RSU | 2025-11-10 | — | — | 174,167 | — | 228,159 |
| Arnon Rosenthal | RSU | 2025-07-01 | — | — | 137,125 | — | 194,717 |
| Neil Berkley | OPTION | 2025-07-01 | — | — | 18,000 | — | 17,566 |
| Neil Berkley | OPTION | 2025-05-15 | — | — | 12,975 | — | 9,951 |
| Sara Kenkare | OPTION | 2025-07-01 | — | — | 18,250 | — | 17,810 |
| Neil Berkley | RSU | 2025-11-10 | — | — | 65,000 | — | 85,150 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Neil Berkley | $128,135 | $0 | $219,202 | 0.0% |
| Arnon Rosenthal | 422,876 | 0 | 558,216 | 0.0% |
| Sara Kenkare | 77,710 | 0 | 17,810 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Neil Berkley | Option | 5,407 | 1.11 | — |
| Neil Berkley | RSU | 9,725 | — | 15,171 |
| Neil Berkley | Option | 10,500 | 1.42 | — |
| Arnon Rosenthal | Option | 24,885 | 9.46 | — |
| Arnon Rosenthal | Option | 26,659 | 1.42 | — |
| Neil Berkley | RSU | 59,584 | — | 92,951 |
| Arnon Rosenthal | Option | 60,730 | 6.48 | — |
| Arnon Rosenthal | RSU | 68,563 | — | 106,958 |
| Neil Berkley | RSU | 95,982 | — | 149,732 |
| Arnon Rosenthal | RSU | 99,401 | — | 155,066 |
| Neil Berkley | RSU | 100,000 | — | 156,000 |
| Arnon Rosenthal | RSU | 159,654 | — | 249,060 |
| Neil Berkley | Option | 190,938 | 1.31 | — |
| Arnon Rosenthal | RSU | 356,127 | — | 555,558 |
| Arnon Rosenthal | Option | 511,615 | 1.31 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Richard H. SchellerIndependent | $45,000 | $67,364 | $10,661 | — | $100,000 | $223,025 |
| Mark AltmeyerIndependent | 65,522 | 46,781 | 10,661 | — | — | 122,964 |
| Errol De SouzaIndependent | 62,500 | 46,781 | 10,661 | — | — | 119,942 |
| Elizabeth GarofaloIndependent | 60,000 | 46,781 | 10,661 | — | — | 117,442 |
| Paula HammondIndependent | 57,500 | 46,781 | 10,661 | — | — | 114,942 |
| Kristine YaffeIndependent | 55,000 | 46,781 | 10,661 | — | — | 112,442 |
| David WehnerIndependent | 29,107 | 0 | 0 | — | — | 29,107 |
Board fee structure and ownership guideline
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | $46,781 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $374,629 |
| Equity awards (grant-date value) | $301,269 |
| All other compensation | $100,000 |
| Total cost of the board | $775,898 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Alector as a peer
Companies that benchmark against ALEC
24 companies name ALEC as a compensation peer
- Arcus Biosciences, Inc.RCUSFY2025
- ARS Pharmaceuticals, Inc.SPRYFY2025
- ARVINAS, INC.ARVNFY2025
- Atea Pharmaceuticals, Inc.AVIRFY2025
- aTYR PHARMA INCATYRFY2025
- Cartesian Therapeutics, Inc.RNACFY2025
- Denali Therapeutics Inc.DNLIFY2025
- DYNAVAX TECHNOLOGIES CORPDVAXFY2024
- Gossamer Bio, Inc.GOSSFY2025
- Olema Pharmaceuticals, Inc.OLMAFY2025
- Personalis, Inc.PSNLFY2025
- PLIANT THERAPEUTICS, INC.PLRXFY2025
- Praxis Precision Medicines, Inc.PRAXFY2025
- Relay Therapeutics, Inc.RLAYFY2025
- SOLENO THERAPEUTICS INCSLNOFY2024
- Stoke Therapeutics, Inc.STOKFY2025
- SUTRO BIOPHARMA, INC.STROFY2025
- uniQure N.V.QUREFY2025
- Wave Life Sciences, Inc.WVEFY2025
- Xencor IncXNCRFY2025
- Zymeworks Inc.ZYMEFY2025
Each company listed discloses ALEC in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ALEC in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
GANX Gain Therapeutics, Inc.OVID Ovid Therapeutics Inc.ASMB Assembly Biosciences, Inc.ABOS Acumen Pharmaceuticals, Inc.BOC Boston
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Assembly Biosciences, Inc. | 2025 | Jason Okazaki | $647,500 | $661,671 | $573,574 | $585,000 | $2,482,987 |
| 2 | Alector | 2025 | Arnon Rosenthal | 678,100 | 422,876 | 558,216 | 325,488 | 1,995,018 |
| 3 | Acumen Pharmaceuticals, Inc. | 2025 | Daniel O'Connell | 646,354 | 412,482 | 478,338 | 305,725 | 1,863,567 |
| 4 | Ovid Therapeutics Inc. | 2025 | Margaret Alexander | 515,000 | 24,806 | 118,466 | 350,000 | 1,022,272 |
| 5 | Boston | 2025 | Adam Peterson | 639,000 | 0 | 0 | 0 | 671,164 |
| — | Gain Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Alector | 80% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Acumen Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Assembly Biosciences, Inc. | not disclosed | Options 100 | No | Alpine Rewards, LLC |
| Boston | not disclosed | RSU 100 | not disclosed | not disclosed |
| Gain Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Ovid Therapeutics Inc. | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLP |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-17 | 58,652,335 | 2,492,538 | 11,082 | 95.91% | Passed |
| 2025 | 2025-06-11 | 68,738,538 | 1,141,227 | 136,670 | 98.17% | Passed |
| 2024 | 2024-06-12 | 72,009,466 | 858,589 | 60,804 | 98.74% | Passed |
| 2023 | 2023-06-14 | 58,053,865 | 3,397,559 | 143,263 | 94.25% | Passed |
| 2022 | 2022-06-16 | 62,031,465 | 1,137,494 | 39,614 | 98.14% | Passed |
| 2021 | 2021-06-17 | 51,877,002 | 359,457 | 64,146 | 99.19% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-17 | 95.91%a |
| 2025 | 2025-06-11 | 98.17%b |
| 2024 | 2024-06-12 | 98.74%c |
a. Approved under the standard stated in the filing — “Abstentions are considered votes present and entitled to vote on this proposal, and thus, will have the same effect as a vote "AGAINST" the proposal.”.
b. Approved under the standard stated in the filing — “Abstentions are considered votes present and entitled to vote on this proposal, and thus, will have the same effect as a vote "AGAINST" the proposal.”.
c. Approved under the standard stated in the filing — “Abstentions are considered votes present and entitled to vote on this proposal, and thus, will have the same effect as a vote "AGAINST" the proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Richard H. Scheller | Director | 2026-06-01 | A | 10,833 | $0 | $0 | Common | Form 4 ↗ |
| Arnon Rosenthal | Director | 2026-06-02 | D | 87,216 | 2 | 172,191 | Common | Form 4 ↗ |
| Neil Berkley | CFO & Chief Business Officer | 2026-06-02 | D | 19,360 | 2 | 38,221 | Common | Form 4 ↗ |
| Grace Wong-Sarad | Principal Accounting Officer | 2026-06-02 | D | 5,709 | 2 | 11,271 | Common | Form 4 ↗ |
| Grace Wong-Sarad | Principal Accounting Officer | 2026-06-03 | D | 3,475 | 2 | 6,543 | Common | Form 4 ↗ |
| Mark Altmeyer | Director | 2026-06-17 | A | 28,700 | 0 | 0 | Common | Form 4 ↗ |
| Kristine Yaffe | Director | 2026-06-17 | A | 9,450 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Louis J. Lavigne Jr | Director | 2026-06-17 | A | 28,700 | 0 | 0 | Common | Form 4 ↗ |
| Errol B. Desouza | Director | 2026-06-17 | A | 9,450 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Errol B. Desouza | Director | 2026-06-17 | A | 28,700 | 0 | 0 | Common | Form 4 ↗ |
| Mark Altmeyer | Director | 2026-06-17 | A | 9,450 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Paula Hammond | Director | 2026-06-17 | A | 9,450 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kristine Yaffe | Director | 2026-06-17 | A | 28,700 | 0 | 0 | Common | Form 4 ↗ |
| Louis J. Lavigne Jr | Director | 2026-06-17 | A | 9,450 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Paula Hammond | Director | 2026-06-17 | A | 28,700 | 0 | 0 | Common | Form 4 ↗ |
| Elizabeth Garofalo | Director | 2026-06-17 | A | 9,450 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard H. Scheller | Director | 2026-06-17 | A | 9,450 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elizabeth Garofalo | Director | 2026-06-17 | A | 28,700 | 0 | 0 | Common | Form 4 ↗ |
| Richard H. Scheller | Director | 2026-06-17 | A | 28,700 | 0 | 0 | Common | Form 4 ↗ |
| Grace Wong-Sarad | Principal Accounting Officer | 2026-07-09 | A | 20,000 | 0 | 0 | Common | Form 4 ↗ |
| Arnon Rosenthal | Director | 2026-08-19 | A | 350,000 | 0 | 0 | Common | Form 4 ↗ |
| Arnon Rosenthal | Director | 2026-08-19 | A | 350,000 | 0 | 0 | Common | Form 4 ↗ |
| Arnon Rosenthal | Director | 2026-08-19 | A | 350,000 | 0 | 0 | Common | Form 4 ↗ |
| Arnon Rosenthal | Director | 2026-08-19 | D | 1,050,000 | 0 | 0 | Common | Form 4 ↗ |
| Grace Wong-Sarad | Principal Accounting Officer | 2026-09-02 | D | 656 | 3 | 1,804 | Common | Form 4 ↗ |
| Grace Wong-Sarad | Principal Accounting Officer | 2026-09-03 | D | 5,165 | 3 | 13,767 | Common | Form 4 ↗ |
| Arnon Rosenthal | Director | 2026-09-03 | D | 72,606 | 3 | 193,473 | Common | Form 4 ↗ |
| Neil Berkley | CFO & Chief Business Officer | 2026-09-03 | D | 29,251 | 3 | 77,948 | Common | Form 4 ↗ |
| Grace Wong-Sarad | Principal Accounting Officer | 2026-09-04 | D | 3,625 | 3 | 9,094 | Common | Form 4 ↗ |
| Arnon Rosenthal | Director | 2026-10-13 | A | 132,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Arnon Rosenthal | Director | 2026-10-13 | D | 132,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Arnon Rosenthal | Director | 2026-10-13 | A | 417,213 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Arnon Rosenthal | Director | 2026-10-13 | D | 119,446 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Arnon Rosenthal | Director | 2026-10-13 | D | 417,213 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Arnon Rosenthal | Director | 2026-10-13 | D | 457,038 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Arnon Rosenthal | Director | 2026-10-13 | D | 520,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Arnon Rosenthal | Director | 2026-10-13 | D | 275,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Arnon Rosenthal | Director | 2026-10-13 | D | 500,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Arnon Rosenthal | Director | 2026-10-13 | A | 275,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Grace Wong-Sarad | Principal Accounting Officer | 2026-10-13 | A | 11,309 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Grace Wong-Sarad | Principal Accounting Officer | 2026-10-13 | D | 11,309 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Grace Wong-Sarad | Principal Accounting Officer | 2026-10-13 | D | 11,552 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Grace Wong-Sarad | Principal Accounting Officer | 2026-10-13 | D | 10,228 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Grace Wong-Sarad | Principal Accounting Officer | 2026-10-13 | D | 20,454 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Grace Wong-Sarad | Principal Accounting Officer | 2026-10-13 | A | 20,454 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Grace Wong-Sarad | Principal Accounting Officer | 2026-10-13 | A | 20,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Grace Wong-Sarad | Principal Accounting Officer | 2026-10-13 | D | 13,842 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Grace Wong-Sarad | Principal Accounting Officer | 2026-10-13 | D | 20,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Grace Wong-Sarad | Principal Accounting Officer | 2026-10-13 | A | 11,552 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Arnon Rosenthal | Director | 2026-10-13 | A | 457,038 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Grace Wong-Sarad | Principal Accounting Officer | 2026-10-13 | A | 10,228 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Grace Wong-Sarad | Principal Accounting Officer | 2026-10-13 | A | 13,842 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Arnon Rosenthal | Director | 2026-10-13 | A | 520,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Arnon Rosenthal | Director | 2026-10-13 | A | 500,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Arnon Rosenthal | Director | 2026-10-13 | A | 119,446 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Arnon Rosenthal | Director | 2026-10-14 | A | 978,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Neil Berkley | CFO & Chief Business Officer | 2026-10-14 | A | 44,567 | 0 | 0 | Common | Form 4 ↗ |
| Grace Wong-Sarad | Principal Accounting Officer | 2026-10-14 | A | 55,555 | 0 | 0 | Common | Form 4 ↗ |
| Arnon Rosenthal | Director | 2026-10-14 | A | 217,500 | 0 | 0 | Common | Form 4 ↗ |
| Neil Berkley | CFO & Chief Business Officer | 2026-10-14 | A | 190,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Grace Wong-Sarad | Principal Accounting Officer | 2026-10-14 | A | 83,435 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (94 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Arnon Rosenthal. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · page 31. As printed: 1,995,018. View filing ↗
- Section 01, Sara Kenkare-Mitra. DEF 14A, filed 2026-04-28. Section “Executive Compensation”. As printed: 1,575,150. View filing ↗
- Section 01, Neil Berkley. DEF 14A, filed 2026-04-28. Section “Executive Compensation”. As printed: 1,052,459. View filing ↗
- Section 03, Neil Berkley OPTION. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Neil Berkley RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Arnon Rosenthal OPTION. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Sara Kenkare RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Arnon Rosenthal OPTION. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Arnon Rosenthal RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Arnon Rosenthal RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Neil Berkley OPTION. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Neil Berkley OPTION. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Sara Kenkare OPTION. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Neil Berkley RSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-28. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Richard H. Scheller. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 223,025. View filing ↗
- Section 08, Mark Altmeyer. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 122,964. View filing ↗
- Section 08, Errol De Souza. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 119,942. View filing ↗
- Section 08, Elizabeth Garofalo. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 117,442. View filing ↗
- Section 08, Paula Hammond. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 114,942. View filing ↗
- Section 08, Kristine Yaffe. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 112,442. View filing ↗
- Section 08, David Wehner. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 29,107. View filing ↗
- Section 02, Richard H. Scheller 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arnon Rosenthal 2026-06-02. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Neil Berkley 2026-06-02. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Grace Wong-Sarad 2026-06-02. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Grace Wong-Sarad 2026-06-03. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Altmeyer 2026-06-17. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristine Yaffe 2026-06-17. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Louis J. Lavigne Jr 2026-06-17. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Errol B. Desouza 2026-06-17. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Errol B. Desouza 2026-06-17. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Altmeyer 2026-06-17. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paula Hammond 2026-06-17. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristine Yaffe 2026-06-17. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Louis J. Lavigne Jr 2026-06-17. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paula Hammond 2026-06-17. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth Garofalo 2026-06-17. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard H. Scheller 2026-06-17. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elizabeth Garofalo 2026-06-17. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard H. Scheller 2026-06-17. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Grace Wong-Sarad 2026-07-09. Form 4, filed 2026-07-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arnon Rosenthal 2026-08-19. Form 4, filed 2026-08-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arnon Rosenthal 2026-08-19. Form 4, filed 2026-08-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arnon Rosenthal 2026-08-19. Form 4, filed 2026-08-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arnon Rosenthal 2026-08-19. Form 4, filed 2026-08-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Grace Wong-Sarad 2026-09-02. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Grace Wong-Sarad 2026-09-03. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arnon Rosenthal 2026-09-03. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Neil Berkley 2026-09-03. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Grace Wong-Sarad 2026-09-04. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arnon Rosenthal 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arnon Rosenthal 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arnon Rosenthal 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arnon Rosenthal 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arnon Rosenthal 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arnon Rosenthal 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arnon Rosenthal 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arnon Rosenthal 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arnon Rosenthal 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arnon Rosenthal 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Grace Wong-Sarad 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Grace Wong-Sarad 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Grace Wong-Sarad 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Grace Wong-Sarad 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Grace Wong-Sarad 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Grace Wong-Sarad 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Grace Wong-Sarad 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Grace Wong-Sarad 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Grace Wong-Sarad 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Grace Wong-Sarad 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arnon Rosenthal 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Grace Wong-Sarad 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Grace Wong-Sarad 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arnon Rosenthal 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arnon Rosenthal 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arnon Rosenthal 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arnon Rosenthal 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Neil Berkley 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Grace Wong-Sarad 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arnon Rosenthal 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Neil Berkley 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Grace Wong-Sarad 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-17. Item 5.07 · say-on-pay result. As reported: 95.91% (votes for as printed: 58,652,335). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-13. Item 5.07 · say-on-pay result. As reported: 98.17% (votes for as printed: 68,738,538). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-12. Item 5.07 · say-on-pay result. As reported: 98.74% (votes for as printed: 72,009,466). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 374,629 + equity 301,269 + all other 100,000 = 775,898, summed across the director compensation table rows.
- Assembly Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Assembly Biosciences, Inc.'s own proxy. As printed: 2,482,987. View filing ↗
- Alector (subject), Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Alector's own proxy. As printed: 1,995,018. View filing ↗
- Acumen Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Acumen Pharmaceuticals, Inc.'s own proxy. As printed: 1,863,567. View filing ↗
- Ovid Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Ovid Therapeutics Inc.'s own proxy. As printed: 1,022,272. View filing ↗
- Boston, Section 10b CEO total. DEF 14A, filed 2026-07-01. CEO total compensation as printed in Boston's own proxy. As printed: 671,164. View filing ↗